Axosin 500 mg/vial (IV Injection)

500 mg vial: ৳ 120.46

Medicine Details

Category Details
Generic Ceftriaxone sodium
Company Ibn sina pharmaceuticals ltd
Also available as
Axosin 250 mg injection Axosin 500 mg injection Axosin 1 gm injection Axosin 1 gm injection Axosin 2 gm injection

Indications

  • Lower respiratory tract infections
  • Acute Bacterial Otitis Media
  • Skin and skin structure infections
  • Urinary tract infections
  • Gonorrhea
  • Bacterial Septicemia
  • Bone and joint infections
  • Meningitis
  • Prevention of postoperative infections
  • Perioperative prophylaxis of infections associated with surgery

Pharmacology

Ceftriaxone is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins, Ceftriaxone kills bacteria by interfering with the synthesis of the bacterial cell wall. Ceftriaxone has a high degree of stability in the presence of beta lactamases. A remarkable feature of Ceftriaxone is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. Ceftriaxone is not metabolized in the body. About 40-65% of a dose of Ceftriaxone is excreted unchanged in the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and microbiologically inactive compound. The drug is highly protein bound (95%).

Dosage

  • Adult:
    • 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day)
  • Infants and Children (01 month or older):
    • 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day)
  • Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual duration is 4 to 14 days; in complicated infections, longer therapy may be required.

Administration

  • For Intramuscular Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g Ceftriaxone in 3.5 ml of Lidocaine HCI 1% injection.
  • For Intravenous Injection:
    • 250 mg or 500 mg Ceftriaxone should be dissolved in 5 ml of Water for injection
    • 1 g Ceftriaxone in 10 ml of Water for injection USP
    • 2 g Ceftriaxone in 20 ml of Water for injection.
  • Injection time: Administered over 2-4 minutes by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL.
  • Test dose: Before starting treatment through Ceftriaxone injection, patient tolerance test should be checked by administration of a test dose.
  • Solution stability: The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 6 hours at room temperature or 24 hours at 5°C.

Interaction

No drug interactions have been reported.

Contraindications

Ceftriaxone should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.

Side Effects

  • Gastrointestinal effects:
    • Diarrhea
    • Nausea
    • Vomiting
    • Stomatitis
    • Glossitis
  • Cutaneous reactions:
    • Rash
    • Pruritus
    • Urticaria
    • Edema
    • Erythema multiforme
  • Hematologic reactions:
    • Eosinophilia
    • Thrombocytopenia
    • Leucopenia
    • Anemia
    • Neutropenia
  • Hepatic reactions:
    • Elevations of SGOT or SGPT
    • Bilirubinemia
  • CNS reactions:
    • Nervousness
    • Confusion
    • Sleep disturbances
    • Headache
    • Hyperactivity
    • Convulsion
    • Hypertonia
    • Dizziness
  • Local phlebitis: Occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes.

Pregnancy & Lactation

Its safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of Ceftriaxone are excreted in human milk. Caution should be exercised when Ceftriaxone is administered to a lactating mother.

Precautions & Warnings

  • Anaphylactic shock: Cannot be ruled out even if a thorough patient history is taken. Immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid are required.
  • Gallbladder findings: In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. Conservative, nonsurgical management is recommended.
  • Prolonged treatment: The blood picture should be checked at regular intervals.

Use in Special Populations

Axosin must not be given to neonates if the neonates is premature and newborn (up to 28 days of age).

Overdose Effects

There is no specific antidote. Treatment of overdosage should be symptomatic.

Therapeutic Class

Third generation Cephalosporins

Storage Conditions

Vial store in a cool, dry place (below 30°C), away from light & moisture. Keep out of the reach of children.

Related Brands